For ads-free news, click here.
A recent study has linked the use of Ozempic and Wegovy, medications used for weight loss and diabetes management, to an increased risk of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss.
The study found that patients taking semaglutide, the active ingredient in these drugs, had a higher chance of developing NAION compared to those taking other diabetes medications.
However, the study’s methodology and the actual incidence rate of NAION among users have been questioned by some, suggesting that the reported risk might be overstated.
Despite the concerns, experts emphasize that the benefits of controlling diabetes, such as reducing the risk of heart, liver, kidney, and brain diseases, should be weighed against the potential risks associated with these medications.
VIDEO
A new study showing the use of Ozempic & Wegovy from $NVO may be linked to irreversible vision loss. @ScottGottliebMD breaks down the risk: pic.twitter.com/zyLodzRsNX
— Squawk Box (@SquawkCNBC) July 5, 2024
